The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Subscribe To Our Newsletter & Stay Updated
